S[IR]{.smallcaps}---Cui et al. \[[@ref1]\] recently described pronounced lymphopenia and low counts of CD4^+^ cells, CD8^+^ cells, and B cells in patients with severe acute respiratory syndrome (SARS). On the basis of these low cell counts, Cui et al. \[[@ref1]\] suggested that SARS coronavirus (SARS-CoV) might damage lymphocytes and concluded that the immune system was impaired during the course of SARS. However, Cui et al. \[[@ref1]\] did not provide direct evidence to support their hypothesis.

Low counts of both CD4^+^ and CD8^+^ cells in the peripheral circulation do not always indicate that the immune system is impaired: redistribution of lymphocytes among peripheral and secondary lymphoid organs and migration of these cells to inflamed tissues caused by infections may also result in lymphopenia. Postthymus naive T cells do not reside in any single lymphoid organ but, rather, circulate continuously between blood and lymph through a specialized T cell zone in secondary lymphoid tissues, which forms part of the "recirculating lymphocyte pool."

Neither splenectomy nor ablation of bone marrow by radioactive isotope therapy reduces the number of lymphocytes, and thymectomy in adult mice causes only a very slow decrease in the size of the recirculating lymphocyte pool. These findings suggest that splenic atrophy and pathological changes in lymph nodes observed in patients with SARS \[[@ref2]\] were not the causes of lymphopenia. Although SARS-CoV RNA was detected in PBMCs obtained from patients with SARS \[[@ref5]\], no SARS-CoV was recovered from splenic, lymphatic, and bone marrow specimens obtained from patients with fatal cases \[[@ref3]\]. This finding indicated that the pathological presentations in lymphoid organs were unlikely to have been directly caused by the virus.

If SARS-CoV was directly detrimental to lymphocytes, the damage should start at the beginning of infection and continue through the incubation period, resulting in a decreased lymphocyte count after the onset of SARS. However, although most patients had mild to moderate decreased lymphocyte counts during the early phase of illness \[[@ref6], [@ref7]\], many patients had normal lymphocyte counts at the onset of symptoms, and some even had increased CD4^+^ and CD8^+^ cell counts during the first week of illness \[[@ref3]\].

Clinically, there is no evidence that the onset of SARS is associated with impairment of the immune system. SARS is characterized by respiratory symptoms and signs correlated with pulmonary lesions caused by SARS-CoV infection. At the time of writing, no report has shown that the initial manifestation of SARS is caused by immunosuppression (e.g., AIDS), and only a small portion of the patients have had secondary bacterial infections---which were easily treatable---during the late course of illness, despite receipt of corticosteroid treatment \[[@ref8]\]. The effectiveness of corticosteroid therapy in stopping the progression of pulmonary lesions in patients with SARS also suggests that SARS is not associated with the impairment of the immune system but is associated with immunopathological damage \[[@ref9]\].

Cui et al. \[[@ref1]\] also found that 76% of patients with SARS had a low B cell count. However, the immune function of B cells in patients with SARS appeared not to have been impaired, because specific anti--SARS-CoV was detected as early as day 10 after the onset of illness \[[@ref8]\], 93%--100% of the patients had seroconversion to anti--SARS-CoV after week 3 \[[@ref8], [@ref10]\], and the level of specific IgG remained high for at least 3 months \[[@ref10]\].

In conclusion, although lymphopenia does occur in patients with SARS, no evidence supports the position that SARS-CoV damages lymphocytes. Humoral immune response to SARS-CoV is not damaged in patients with SARS. Before in vitro and in vivo cellular immune responses are investigated, it would be cautious to conclude that the immune system is impaired in patients with SARS.
